{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:42:07Z","timestamp":1761972127522,"version":"build-2065373602"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.2169\/internalmedicine.4577-24","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:09:03Z","timestamp":1761948543000},"page":"3103-3106","source":"Crossref","is-referenced-by-count":0,"title":["Importance of Vaccine Adjuvants: A Comparative Study of Antibody Acquisition Rates and Levels Before and After Adjuvant Change in the Hepatitis B Vaccine"],"prefix":"10.2169","volume":"64","author":[{"given":"Keiichiro","family":"Yoneyama","sequence":"first","affiliation":[{"name":"Health Service Center, Showa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, Showa University School of Pharmacy, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Tsuboya","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, Showa University School of Pharmacy, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuhiko","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Okajima","sequence":"additional","affiliation":[{"name":"Health Service Center, Showa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Health Service Center, Showa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. World Health Organization. Hepatitis B [Internet]. 2024 [cited 2024 Jan 25]. Available from: https:\/\/www.who.int\/newsroom\/factsheets\/detail\/hepatitis-b"},{"key":"2","unstructured":"2. Number of new hepatitis B infections worldwide in 2022, by World Health Organization (WHO) region [Internet]. [cited 2024 Jan 25]. Available from: https:\/\/www.statista.com\/statistics\/1480421\/number-of-new-hepatitis-b-infections-worldwide-by-who-region\/."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 384: 2053-2063, 2014.","DOI":"10.1016\/S0140-6736(14)60220-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yoda T, Katsuyama H. Analysis of antibody-negative medical students after hepatitis B vaccination in Japan. Hum Vaccin Immunother 17: 852-856, 2021.","DOI":"10.1080\/21645515.2020.1788309"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kishino H, Takahashi K, Sawata M, Tanaka Y. Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults. Hum Vaccin Immunother 14: 1773-1778, 2018.","DOI":"10.1080\/21645515.2018.1452578"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Doi H, Yoshio S, Yoneyama K, et al. Immune determinants in the acquisition and maintenance of antibody to hepatitis B surface antigen in adults after first-time hepatitis B vaccination. Hepatol Commun 3: 812-824, 2019.","DOI":"10.1002\/hep4.1357"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open 3: e2027577, 2020.","DOI":"10.1001\/jamanetworkopen.2020.27577"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Champion CR. Heplisav-B: a hepatitis B vaccine with a novel adjuvant. Ann Pharmacother 55: 783-791, 2021.","DOI":"10.1177\/1060028020962050"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wong K, Bruxvoort K, Slezak J, et al. Hepatitis B vaccine and risk of acute myocardial infarction among individuals with diabetes mellitus. Pharmacoepidemiol Drug Saf 30: 1441-1446, 2021.","DOI":"10.1002\/pds.5327"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study. JHEP Rep 3: 100361, 2021.","DOI":"10.1016\/j.jhepr.2021.100361"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sucher AJ, Sucher BJ, Chahine EB. PreHevbrio: a new 3-antigen hepatitis B vaccine for adults. Ann Pharmacother 57: 325-332, 2023.","DOI":"10.1177\/10600280221114469"},{"key":"12","unstructured":"12. Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 62: 1-19, 2013."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yoneyama K, Suzuki A, Suzuki K. Comparison of seroconversion rates with three kinds of recombinant hepatitis B vaccines. Showa Univ J Med Sci 11: 69-73, 1999.","DOI":"10.15369\/sujms1989.11.69"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsumoto M, Tatematsu M, Nishikawa F, et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production <i>in vivo<\/i>. Nat Commun 6: 6280, 2015.","DOI":"10.1038\/ncomms7280"},{"key":"15","first-page":"383","volume":"72","author":"S Kuriyama","year":"1988","unstructured":"15. Kuriyama S, Tsujii T, Ishizaka S, et al. Enhancing effects of oral adjuvants on anti-HBs responses induced by hepatitis B vaccine. Clin Exp Immunol 72: 383-389, 1988.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sasaki E, Asanuma H, Momose H, Furuhata K, Mizukami T, Hamaguchi I. Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses. PLOS Pathog 17: e1009890, 2021.","DOI":"10.1371\/journal.ppat.1009890"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/21\/64_4577-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:26:46Z","timestamp":1761967606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/21\/64_4577-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4577-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"article-number":"4577-24"}}